

David C Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6924861/publications.pdf>

Version: 2024-02-01

199
papers

33,619
citations

12303

69
h-index

3815

178
g-index

202
all docs

202
docs citations

202
times ranked

38781
citing authors

#	ARTICLE	IF	CITATIONS
1	ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.. Journal of Clinical Oncology, 2022, 40, 502-502.	0.8	0
2	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). International Journal of Molecular Sciences, 2022, 23, 4.	1.8	6
3	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. Urology, 2022, 167, 171-178.	0.5	4
4	Reagent and analyte ion hydrates in secondary electrospray ionization mass spectrometry (SESI-MS), their equilibrium distributions and dehydration in an ion transfer capillary: Modelling and experiments. Rapid Communications in Mass Spectrometry, 2021, 35, e9047.	0.7	12
5	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	3.4	65
6	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	0.8	65
7	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 28-37.	2.9	62
8	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
9	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer, 2020, 123, 1590-1598.	2.9	57
10	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clinical Cancer Research, 2020, 26, 1247-1257.	3.2	54
11	Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS. Clinical Mass Spectrometry, 2020, 16, 18-24.	1.9	46
12	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Investigational New Drugs, 2020, 38, 1421-1429.	1.2	33
13	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 332-339.e2.	0.9	5
14	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs, 2019, 37, 297-306.	1.2	51
15	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology, 2019, 5, 1411.	3.4	388
16	Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. Clinical Genitourinary Cancer, 2019, 17, e592-e601.	0.9	9
17	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Management and Research, 2019, Volume 11, 10463-10476.	0.9	56
18	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Investigational New Drugs, 2019, 37, 461-472.	1.2	51

#	ARTICLE	IF	CITATIONS
19	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1529-1554.	2.3	174
20	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Molecular Cancer Research, 2018, 16, 643-654.	1.5	33
21	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. Medical Oncology, 2018, 35, 21.	1.2	3
22	What is the real utility of breath ammonia concentration measurements in medicine and physiology?. Journal of Breath Research, 2018, 12, 027102.	1.5	30
23	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. Journal of Clinical Oncology, 2018, 36, 617-623.	0.8	18
24	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology, 2018, 36, 1675-1684.	0.8	584
25	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	0.8	288
26	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). Journal of Clinical Oncology, 2018, 36, 3223-3230.	0.8	267
27	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	0.8	169
28	Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. Cancer, 2018, 124, 3971-3974.	2.0	2
29	Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 189-199.	1.0	2
30	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	7.7	321
31	Academic Cancer Center Phase I Program Development. Oncologist, 2017, 22, 369-374.	1.9	0
32	A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 7490-7497.	3.2	148
33	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. European Journal of Cancer, 2017, 86, 296-304.	1.3	64
34	A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. European Journal of Cancer, 2017, 83, 229-236.	1.3	28
35	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
36	On the importance of accurate quantification of individual volatile metabolites in exhaled breath. Journal of Breath Research, 2017, 11, 047106.	1.5	17

#	ARTICLE	IF	CITATIONS
37	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	0.8	45
38	Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 433-441.	1.1	11
39	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 271-280.	1.1	2
40	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
41	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016, 1, 59-66.	0.6	6
42	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 1-9.	2.3	25
43	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 155-162.	1.1	66
44	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2016, 21, 402.	1.9	2
45	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
46	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 851-859.	1.1	53
47	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	0.8	385
48	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	1.2	35
49	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558), Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
50	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 777-784.	1.1	17
51	SIFT-MS and FA-MS methods for ambient gas phase analysis: developments and applications in the UK. <i>Analyst</i> , The, 2015, 140, 2573-2591.	1.7	38
52	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
53	Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11057-11057.	0.8	2
54	Phase I study of MEDI0639 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3024-3024.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3615-3615.	0.8	17
56	Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2015, 33, 2531-2531.	0.8	0
57	Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. Bioanalysis, 2014, 6, 843-857.	0.6	65
58	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	0.8	110
59	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 2684-2693.	2.0	105
60	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 692-701.	2.0	91
61	Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. Investigational New Drugs, 2014, 32, 188-194.	1.2	8
62	A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors. Clinical Cancer Research, 2014, 20, 6295-6303.	3.2	138
63	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investigational New Drugs, 2014, 32, 1005-1016.	1.2	29
64	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	0.8	2,015
65	Small-molecule SMAC mimetics as new cancer therapeutics. , 2014, 144, 82-95.		160
66	Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.. Journal of Clinical Oncology, 2014, 32, e13539-e13539.	0.8	2
67	Targeting C-Met/VEGF in Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , 265-276.	0.0	0
68	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemotherapy and Pharmacology, 2013, 72, 1089-1096.	1.1	24
69	Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. Journal of Clinical Oncology, 2013, 31, 412-419.	0.8	405
70	A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder. Urology, 2013, 82, 111-117.	0.5	30
71	Recent SIFT-MS Studies of Volatile Compounds in Physiology, Medicine and Cell Biology. , 2013, , 48-76.		7
72	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2013, 18, 163-173.	1.9	145

#	ARTICLE	IF	CITATIONS
73	Account: On the Features, Successes and Challenges of Selected Ion Flow Tube Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2013, 19, 225-246.	0.5	23
74	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3002-3002.	0.8	47
75	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	13.9	10,727
76	Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2012, 118, 44-53.	2.0	44
77	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 249-257.	1.2	66
78	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012, 30, 749-757.	1.2	72
79	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2012, 30, 4505-4505.	0.8	9
80	Ambient analysis of trace compounds in gaseous media by SIFT-MS. <i>Analyst</i> , 2011, 136, 2009.	1.7	104
81	Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032. <i>Urology</i> , 2011, 77, 1172-1176.	0.5	12
82	Volatile compounds in health and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011, 14, 455-460.	1.3	40
83	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. <i>Science Translational Medicine</i> , 2011, 3, 111ra121.	5.8	531
84	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011, 29, 1432-1440.	1.2	49
85	Progress in SIFT-MS: Breath analysis and other applications. <i>Mass Spectrometry Reviews</i> , 2011, 30, 236-267.	2.8	289
86	Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy. <i>Cancer</i> , 2011, 117, 2419-2425.	2.0	15
87	Direct, rapid quantitative analyses of BVOCs using SIFT-MS and PTR-MS obviating sample collection. <i>TrAC - Trends in Analytical Chemistry</i> , 2011, 30, 945-959.	5.8	98
88	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3924-3932.	3.2	69
89	American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3388-3404.	0.8	246
90	Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 105-111.	0.5	21

#	ARTICLE	IF	CITATIONS
91	Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. <i>Journal of Clinical Oncology</i> , 2009, 27, 2772-2778.	0.8	36
92	Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma. <i>Cancer</i> , 2009, 115, 4110-4117.	2.0	117
93	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Tj ETQq1 1 0.784314 184 /Over	2.0	184
94	The quantification of carbon dioxide in humid air and exhaled breath by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 1419-1425.	0.7	28
95	Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 511-517.	0.4	65
96	A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219). <i>Journal of Urology</i> , 2009, 181, 2476-2481.	0.2	69
97	An exploratory comparative study of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 526-532.	0.7	116
98	A selected ion flow tube mass spectrometry study of ammonia in mouth- and nose-exhaled breath and in the oral cavity. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 783-789.	0.7	88
99	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2008, 113, 975-984.	2.0	192
100	Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. <i>Journal of Breath Research</i> , 2008, 2, 037013.	1.5	133
101	Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 180, 2384-2388.	0.2	54
102	Treatment of Biochemical Recurrence of Prostate Cancer With Granulocyte-Macrophage Colony-Stimulating Factor Secreting, Allogeneic, Cellular Immunotherapy. <i>Journal of Urology</i> , 2008, 180, 2011-2018.	0.2	22
103	Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life. <i>Journal of Clinical Oncology</i> , 2007, 25, 4171-4177.	0.8	188
104	The concentration distributions of some metabolites in the exhaled breath of young adults. <i>Journal of Breath Research</i> , 2007, 1, 026001.	1.5	46
105	Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/nerve Growth Factor-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 2218-2224.	0.8	355
106	Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 4-83 years. <i>Journal of Breath Research</i> , 2007, 1, 011001.	1.5	83
107	Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. <i>Journal of Breath Research</i> , 2007, 1, 014004.	1.5	110
108	Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 318-322.	0.9	8

#	ARTICLE	IF	CITATIONS
109	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. <i>Cancer</i> , 2007, 110, 2809-2818.	2.0	283
110	Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Maintenance Sunitinib Versus Placebo After Chemotherapy for Patients with Advanced Urothelial Carcinoma: Scientific Rationale and Study Design. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 460-463.	0.9	33
111	A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006, 27, 321-337.	1.2	323
112	Generation of volatile compounds on mouth exposure to urea and sucrose: implications for exhaled breath analysis. <i>Physiological Measurement</i> , 2006, 27, N7-N17.	1.2	42
113	A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006, 27, 637-648.	1.2	122
114	A longitudinal study of breath isoprene in healthy volunteers using selected ion flow tube mass spectrometry (SIFT-MS). <i>Physiological Measurement</i> , 2006, 27, 13-22.	1.2	131
115	Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer. <i>Oncology</i> , 2006, 71, 168-175.	0.9	68
116	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. <i>Clinical Genitourinary Cancer</i> , 2006, 4, 299-302.	0.9	73
117	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2006, 106, 1715-1721.	2.0	10
118	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. <i>Cancer</i> , 2006, 106, 2617-2623.	2.0	4
119	The increase of breath ammonia induced by niacin ingestion quantified by selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2006, 27, 437-444.	1.2	8
120	Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). <i>Investigational New Drugs</i> , 2005, 23, 79-84.	1.2	68
121	Advances in Prostate Cancer Chemotherapy: A New Era Begins. <i>Ca-A Cancer Journal for Clinicians</i> , 2005, 55, 300-318.	157.7	146
122	Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. <i>Mass Spectrometry Reviews</i> , 2005, 24, 661-700.	2.8	683
123	Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1439-1446.	0.8	188
124	Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 2540-2545.	0.8	79
125	On-line analysis of diesel engine exhaust gases by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 2830-2838.	0.7	26
126	A selected ion flow tube study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with some phenols, phenyl alcohols and cyclic carbonyl compounds in support of SIFT-MS and PTR-MS. <i>International Journal of Mass Spectrometry</i> , 2004, 239, 139-146.	0.7	42

#	ARTICLE	IF	CITATIONS
127	Association between Agent Orange and prostate cancer: a pilot case-control study. <i>Urology</i> , 2004, 63, 757-760.	0.5	35
128	Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. <i>Urology</i> , 2004, 64, 69-73.	0.5	35
129	Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-MS study over 30 days. <i>Physiological Measurement</i> , 2003, 24, 107-119.	1.2	210
130	Chemotherapy for localized, high-risk prostate cancer. <i>Seminars in Radiation Oncology</i> , 2003, 13, 152-157.	1.0	5
131	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003, 98, 269-276.	2.0	34
132	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. <i>Cancer</i> , 2003, 98, 1603-1610.	2.0	35
133	A SIFT study of the reactions of H ₂ ONO ⁺ ions with several types of organic molecules. <i>International Journal of Mass Spectrometry</i> , 2003, 230, 1-9.	0.7	29
134	Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: Results of a pilot study. <i>Psycho-Oncology</i> , 2003, 12, 814-820.	1.0	28
135	Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 845-850.	0.7	137
136	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003, 61, 774-780.	0.5	106
137	Increase of acetone and ammonia in urine headspace and breath during ovulation quantified using selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2003, 24, 191-199.	1.2	44
138	On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. <i>Physiological Measurement</i> , 2002, 23, 477-489.	1.2	78
139	Novel gemcitabine-containing triplets in the management of urothelial cancer. <i>Seminars in Oncology</i> , 2002, 29, 20-24.	0.8	16
140	Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 179-185.	1.1	8
141	A selected ion flow tube (SIFT), study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of alkenes; in support of SIFT-MS. <i>International Journal of Mass Spectrometry</i> , 2002, 218, 87-101.	0.7	59
142	A selected ion flow tube, SIFT, study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of diols. <i>International Journal of Mass Spectrometry</i> , 2002, 218, 227-236.	0.7	32
143	The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 934-941.	0.4	8
144	Kinetics and isotope patterns of ethanol and acetaldehyde emissions from yeast fermentations of glucose and glucose-6,6-d ₂ using selected ion flow tube mass spectrometry: a case study. <i>Rapid Communications in Mass Spectrometry</i> , 2002, 16, 69-76.	0.7	28

#	ARTICLE	IF	CITATIONS
145	Analysis of petrol and diesel vapour and vehicle engine exhaust gases using selected ion flow tube mass spectrometry. Rapid Communications in Mass Spectrometry, 2002, 16, 1124-1134.	0.7	46
146	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with the anaesthetic gases halothane, isoflurane and sevoflurane. Rapid Communications in Mass Spectrometry, 2002, 16, 1860-1870.	0.7	20
147	Quantification of volatile compounds in the headspace of aqueous liquids using selected ion flow tube mass spectrometry. Rapid Communications in Mass Spectrometry, 2002, 16, 2148-2153.	0.7	38
148	COMBINATION CISPLATIN, 5-FLUOROURACIL AND RADIATION THERAPY FOR LOCALLY ADVANCED UNRESECTABLE OR MEDICALLY UNFIT BLADDER CANCER CASES: A SOUTHWEST ONCOLOGY GROUP STUDY. Journal of Urology, 2001, 165, 56-61.	0.2	65
149	Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer. Journal of Clinical Oncology, 2001, 19, 2527-2533.	0.8	198
150	Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2001, 19, 4202-4208.	0.8	300
151	Concurrent use of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ precursor ions for the detection and quantification of diverse trace gases in the presence of air and breath by selected ion-flow tube mass spectrometry. International Journal of Mass Spectrometry, 2001, 209, 81-97.	0.7	66
152	Quantitative selected ion flow tube mass spectrometry: The influence of ionic diffusion and mass discrimination. Journal of the American Society for Mass Spectrometry, 2001, 12, 863-872.	1.2	60
153	On-line measurement of the absolute humidity of air, breath and liquid headspace samples by selected ion flow tube mass spectrometry. Rapid Communications in Mass Spectrometry, 2001, 15, 563-569.	0.7	78
154	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma. Cancer, 2001, 91, 2175-2180.	2.0	7
155	Adjuvant and neoadjuvant therapy in prostate cancer. Seminars in Oncology, 2001, 28, 3-12.	0.8	18
156	A new "online"™ method to measure increased exhaled isoprene in end-stage renal failure. Nephrology Dialysis Transplantation, 2001, 16, 836-839.	0.4	75
157	An investigation of the reactions of H ₃ O ⁺ and O ₂ ⁺ with NO, NO ₂ , N ₂ O and HNO ₂ in support of selected ion flow tube mass spectrometry. , 2000, 14, 646-651.		20
158	Influence of water vapour on selected ion flow tube mass spectrometric analyses of trace gases in humid air and breath. Rapid Communications in Mass Spectrometry, 2000, 14, 1898-1906.	0.7	70
159	Expression of Nuclear Antigen Ki-67 in Prostate Cancer Needle Biopsy and Radical Prostatectomy Specimens. Journal of the National Cancer Institute, 2000, 92, 1941-1942.	3.0	35
160	Trace gases in breath of healthy volunteers when fasting and after a protein-calorie meal: a preliminary study. Journal of Applied Physiology, 1999, 87, 1584-1588.	1.2	160
161	Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 1664-1664.	0.8	158
162	A new concept in cancer care: The supportive care program. American Journal of Hospice and Palliative Medicine, 1999, 16, 713-722.	0.8	19

#	ARTICLE	IF	CITATIONS
163	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with eleven amine structural isomers of c ₅ h ₁₃ n. International Journal of Mass Spectrometry, 1999, 185-187, 139-147.	0.7	30
164	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several aromatic and aliphatic monosubstituted halocarbons. International Journal of Mass Spectrometry, 1999, 189, 213-223.	0.7	53
165	Phase II trial of suramin in patients with metastatic renal cell carcinoma. Investigational New Drugs, 1999, 17, 183-186.	1.2	24
166	A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology, 1999, 44, 511-517.	1.1	6
167	Selected ion flow tube - mass spectrometry: detection and real-time monitoring of flavours released by food products. Rapid Communications in Mass Spectrometry, 1999, 13, 585-596.	0.7	120
168	Selected ion flow tube mass spectrometry of urine headspace. , 1999, 13, 724-729.		60
169	Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. Rapid Communications in Mass Spectrometry, 1999, 13, 1354-1359.	0.7	166
170	Quantification of breath isoprene using the selected ion flow tube mass spectrometric analytical method. , 1999, 13, 1733-1738.		81
171	Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer. Drugs, 1999, 58, 127-131.	4.9	4
172	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 1999, 53, 260-266.	0.5	199
173	ORAL CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1999, 26, 333-340.	0.8	6
174	CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1999, 26, 323-331.	0.8	28
175	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several amines and some other nitrogen-containing molecules. International Journal of Mass Spectrometry, 1998, 176, 203-211.	0.7	76
176	SIFT studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with a series of volatile carboxylic acids and esters. International Journal of Mass Spectrometry and Ion Processes, 1998, 172, 137-147.	1.9	118
177	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology, 1998, 52, 257-260.	0.5	164
178	Enhancement of 1,25-Dihydroxyvitamin D ₃ -Mediated Antitumor Activity With Dexamethasone. Journal of the National Cancer Institute, 1998, 90, 134-141.	3.0	92
179	The Selected Ion Flow Tube Method for Workplace Analyses of Trace Gases in Air and Breath: Its Scope, Validation, and Applications. Journal of Occupational and Environmental Hygiene, 1998, 13, 817-823.	0.5	42
180	A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology, 1997, 50, 401-407.	0.5	92

#	ARTICLE	IF	CITATIONS
181	THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1997, 24, 433-437.	0.8	11
182	Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. <i>Kidney International</i> , 1997, 52, 223-228.	2.6	328
183	A phase II trial of all- trans -retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 349-356.	1.1	58
184	All- trans -retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 41, 133-139.	1.1	26
185	Megestrol Acetate in the Treatment of Hormone Refractory Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 308-310.	0.6	32
186	The Novel Selected-ion Flow Tube Approach to Trace Gas Analysis of Air and Breath. , 1996, 10, 1183-1198.		154
187	Application of ion chemistry and the SIFT technique to the quantitative analysis of trace gases in air and on breath. <i>International Reviews in Physical Chemistry</i> , 1996, 15, 231-271.	0.9	130
188	Reactions of H ₃ O ⁺ and OH ⁻ ions with some organic molecules; applications to trace gas analysis in air. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1995, 145, 177-186.	1.9	62
189	Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995, 1, 195-198.	0.8	141
190	Population pharmacokinetics of hydroxyurea in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 417-422.	1.1	38
191	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 65-68.	1.1	18
192	Reactions of Hydrated Hydronium Ions and Hydrated Hydroxide Ions with Some Hydrocarbons and Oxygen-Bearing Organic Molecules. <i>The Journal of Physical Chemistry</i> , 1995, 99, 15551-15556.	2.9	111
193	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 65-68.	1.1	1
194	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 347-354.	1.1	25
195	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 347-354.	1.1	1
196	Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 31, 363-368.	1.1	4
197	A phase I trial of high-dose continuous-infusion hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 139-143.	1.1	10
198	Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 272-276.	1.1	6

#	ARTICLE	IF	CITATIONS
199	Genetic counterselective procedure to isolate interspecific cell hybrids containing single human chromosomes: Construction of cell hybrids and recombinant DNA libraries specific for human chromosomes 3 and 4. Somatic Cell and Molecular Genetics, 1986, 12, 163-174.	0.7	63